Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden Announces Insurance Coverage For OTC COVID-19 Tests

Executive Summary

The White House also announced it would double commitment it made in September for number of OTC test kits to be distributed free by community groups from 25m kits to 50m and would add rural clinics to the program.

You may also be interested in...



Top Republican Senators Criticize Biden Administration For Lack Of COVID-19 Tests

The top GOPers on the Senate health committee want to know what the administration has done with more than $80bn allocated by Congress to ramp up production of COVID-19 tests.

Three OTC COVID-19 Tests Win FDA Clearance After Template Updates

Access Bio’s CareStart COVID-19 Antigen test gives results within 10 minutes, Becton, Dickinson’s BD Veritor within 15 minutes and InBios International’s SCoV-2 Ag Detect within 20 minutes. All three hold emergency use authorizations.

US FTC Says It’s On ‘Solid Ground’ To Bring Cases Following Notices Of Penalty Offense

The US Federal Trade Commission is "fully prepared" to bring forward cases after issuing hundreds of penalty offense notices in April regarding health claims substantiation, and it is likely to seek injunctive and monetary relief, said Samuel Levine, director of the FTC’s Bureau of Consumer Protection, at the National Advertising Division’s annual conference in Philadelphia.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel